Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-line treatment for patients with hypertension: An ALLHAT analysis

被引：0
|
作者：
Heidenreich, PA
Davis, BR
Furberg, CD
Lairson, DR
Pressel, S
Goldman, L
机构：
[1] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2006年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372A / 372A
页数：1
相关论文
共 50 条
  • [41] The Cost-Effectiveness of First-Line Cryoablation vs First-Line Antiarrhythmic Drugs in Canadian Patients With Atrial Fibrillation
    Andrade, Jason G.
    Moss, Joe W. E.
    Kuniss, Malte
    Sadri, Hamid
    Wazni, Oussama
    Sale, Alicia
    Ismyrloglou, Eleni
    Chierchia, Gian Battista
    Kaplon, Rachelle
    Mealing, Stuart
    Bainbridge, Jamie
    Bromilow, Tom
    Lane, Emily
    Khaykin, Yaariv
    CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (04) : 576 - 584
  • [42] Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
    Critchlow, Simone
    Bullement, Ash
    Crabb, Simon
    Jones, Robert
    Christoforou, Katerina
    Amin, Amerah
    Xiao, Ying
    Kapetanakis, Venediktos
    Benedict, Agnes
    Chang, Jane
    Kearney, Mairead
    Eccleston, Anthony
    FUTURE ONCOLOGY, 2024, 20 (08) : 459 - 470
  • [43] Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
    Harrington, Rachel
    Lee, Edward
    Yang, Hongbo
    Wei, Jin
    Messali, Andrew
    Azie, Nkechi
    Wu, Eric Q.
    Spalding, James
    ADVANCES IN THERAPY, 2017, 34 (01) : 207 - 220
  • [44] Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
    Rachel Harrington
    Edward Lee
    Hongbo Yang
    Jin Wei
    Andrew Messali
    Nkechi Azie
    Eric Q. Wu
    James Spalding
    Advances in Therapy, 2017, 34 : 207 - 220
  • [45] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
    Chen, Qiuping
    Sun, Quan
    Zhang, Jing
    Li, Baixue
    Feng, Quansheng
    Liu, Jibin
    PLOS ONE, 2024, 19 (03):
  • [46] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [47] Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    Zhu, Huide
    IMMUNOTHERAPY, 2023, 15 (13) : 1045 - 1055
  • [48] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [49] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [50] Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis
    Luca, Nadia J.
    Burnett, Heather F.
    Ungar, Wendy J.
    Moretti, Myla E.
    Beukelman, Timothy
    Feldman, Brian M.
    Schwartz, Gwen
    Bayoumi, Ahmed M.
    ARTHRITIS CARE & RESEARCH, 2016, 68 (12) : 1803 - 1811
12345